Table I.
Summary of randomized, controlled trials included in the meta-analysis of Crohn’s disease.
| Author (ref) | Mean age | Gender (M/F) | Regimens | Concomitant therapy | Duration | Clinical improvement
|
|
|---|---|---|---|---|---|---|---|
| Antibiotics | Placebo | ||||||
| Arnold et al, 2002 (9) | 45.2 | 28/19 | Cipro 500 mg b.i.d. | Prednisone | 4 weeks | 21/28 | 5/19 |
| Prantera et al, 2006 (8) | 38±12 | 16/11 | Rifaximin 800 mg b.i.d. | Aminosalicylate | 12 weeks | 14/27 | 9/27 |
| West et al, 2004 (10) | 34 | 12/12 | Cipro 500 mg b.i.d. | Infliximab | 6 weeks | 1/11 | 2/13 |
| Steinhart et al, 2002 (7) | 32 | 57/77 | Cipro 500 mg b.i.d. + metro 500 mg b.i.d. | Budesonide | 8 weeks | 22/66 | 21/64 |
| Leiper et al, 2008 (11) | 34 | 17/24 | Clari 1 g/day | 12 weeks | 5/19 | 6/22 | |
| Goodgame et al, 2001 (12) | 39.4±9.2 | 18/13 | Clari 500 mg b.i.d. + ethambutol 15 mg/kg | 12 weeks | 5/9 | 6/9 | |
| Blichfeldt et al, 1978 (13) | 27.5 | 8/12 | Metro 250 mg q.i.d. | Prednisone | 8 weeks | 11/20 | 10/20 |
| Ambrose et al, 1985 (14) | 36.5 | 13/22 | Metro 400 mg b.i.d. | 2 weeks | 12/18 | 6/17 | |
| 4 weeks | 8/18 | 7/17 | |||||
| 6 weeks | 10/16 | 7/14 | |||||
| Ambrose et al, 1985 (14) | 37.0 | 12/21 | Sulfa 960 mg b.i.d. | 2 weeks | 10/16 | 6/17 | |
| 4 weeks | 10/16 | 7/17 | |||||
| Sutherland et al, 1991 (6) | NA | NA | Metro 10–20 mg/kg/day | 16 weeks | 18/63 | 6/36 | |
| Selby et al, 2007 (5) | 36.5±11.3 | 101/112 | Clari 750 mg/day + rifampicin 450 mg/day + clofa 50 mg/day | Prednisone | 16 weeks | 67/102 | 55/111 |
Cipro, ciprofloxacin; metro, metronidazole; clari, clarithromycin; sulfa, sulfamethoxazole; clofa, clofazimine; NA, not available.